These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 9631694

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antiretroviral rounds. When success is a pain.
    Bartlett JG, del Rio C.
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical trials group: two studies are now open to patients who qualify.
    Craig K.
    HIV Clin; 2000 Aug; 12(1):5. PubMed ID: 11810862
    [No Abstract] [Full Text] [Related]

  • 7. Sustiva added to three-drug combination.
    AIDS Patient Care STDS; 1998 Oct; 12(10):803. PubMed ID: 11362030
    [No Abstract] [Full Text] [Related]

  • 8. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
    Moyle GJ, Gazzard BG.
    AIDS; 2002 May 03; 16(7):1086-7. PubMed ID: 11953482
    [No Abstract] [Full Text] [Related]

  • 9. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G.
    J Clin Invest; 2000 Mar 03; 105(6):777-82. PubMed ID: 10727446
    [Abstract] [Full Text] [Related]

  • 10. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
    Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC.
    AIDS; 2002 Mar 08; 16(4):551-60. PubMed ID: 11872998
    [Abstract] [Full Text] [Related]

  • 11. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A, Poggi C, Sayada C, Pellegrino P, Profizi N.
    AIDS; 1997 Feb 08; 11(2):264-6. PubMed ID: 9030385
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001 Feb 08; 12(12):3. PubMed ID: 11570089
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. ACTG 320: last of the body count trials?
    PI Perspect; 1997 Mar 08; (No 21):7. PubMed ID: 11364215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.